Portola Pharmaceuticals, Inc.
(NASDAQ : PTLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.40%70.555.6%$182.80m
CTLTCatalent, Inc. 2.88%97.382.1%$122.62m
VRXValeant Pharmaceuticals International, Inc. 1.93%19.5414.1%$114.98m
BHCBausch Health Cos., Inc. 1.93%19.540.0%$82.27m
JAZZJazz Pharmaceuticals Plc 1.02%143.282.4%$79.60m
GWPHGW Pharmaceuticals Plc 1.65%129.716.1%$68.89m
PRGOPerrigo Co. Plc 0.21%48.036.8%$56.45m
UTHRUnited Therapeutics Corp. 0.35%135.5414.1%$55.32m
SAGESAGE Therapeutics, Inc. -8.62%75.578.6%$53.25m
ARGXargenx SE 6.07%281.590.0%$40.59m
SAVACassava Sciences, Inc. 0.78%7.760.0%$38.85m
ICLRICON plc 1.54%191.144.2%$36.74m
AMRNAmarin Corp. Plc 0.00%4.601.5%$36.00m
BLRXBioLineRx Ltd. 3.11%2.321.8%$35.68m
ICPTIntercept Pharmaceuticals, Inc. -0.32%37.2716.8%$32.30m

Company Profile

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.